Merck (MRK.US) is close to acquiring Verona Pharmaceuticals (VRNA.US) for nearly $10 billion.

According to the 36Kr Finance and Economics APP, it was reported that Merck (MRK.US) is set to reach a deal to acquire respiratory drug maker Verona Pharmaceuticals (VRNA.US) for about $10 billion. Informed sources said that Merck will acquire the biotechnology company at a price of $107 per ADS, representing a 23% premium to the latter's closing price on Tuesday.